June 16, 2020 / 2:52 PM / a month ago

Britain's drug regulator suspends hydroxychloroquine trial recruitment

LONDON, June 16 (Reuters) - Britain’s drug regulator on Tuesday instructed scientists trialling the use of malaria drug hydroxychloroquine for the treatment or prevention of COVID-19 to suspend the recruitment of participants.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it was following “emerging concerns” about the use of the drug, and also cited a UK trial which found no meaningful mortality benefit in patients hospitalised with COVID-19. (Reporting by Alistair Smout, editing by Estelle Shirbon)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below